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The vast majority of malignant gliomas remain incurable by
conventional methods of therapy. Refinement of surgical
techniques by stereotactic resection of the radiological extent
of a glioma alone has not resulted in cure and present
methods of adjuvant therapy are not effective because they
are non-selective: treatment parameters that might eradicate
tumour also do irreparable damage to the normal brain. In
the evaluation of any new form of adjuvant therapy the first
step must therefore be the demonstration of the method's
potential to produce selective glioma necrosis without
damaging the normal brain.
Photodynamic therapy (PDT) has the theoretical potential
for tumour selectivity because of the highly selective
concentration of photosensitisers in glioma tissue. Both
experimental and human tumours contain at least a ten times
higher concentration of photosensitiser than the normal
brain (Boggan et al., 1984; Wharen et al., 1983). The technique
has been used to treat patients for over ten years but this
potential for selectivity has never been realised for two main
reasons (Laws et al., 1981; McCulloch et al., 1984; Perria et
al., 1981). Firstly it is now apparent that the normal brain is
damaged by PDT and treatment parameters that do not
damage normal brain have not yet been identified
(Berenbaum et al., 1986; Rounds et al., 1982; Cheng et al.,
1984). Secondly, the problem of selectivity in the clinical
situation of 'sterilising' a tumour bed following macroscopic
tumour resection is compounded by the fact that infiltrating
tumour tissue receives a lower light dose than normal brain
on the surface. Since the photodynamic reaction depends on
the product of the local light fluence and the local photo-
sensitiser concentration, tumour cells within a tumour bed
will only receive a greater photodynamic dose than normal
brain on the surface at depths where light is attenuated less
than the difference in photosenitiser concentration between
normal brain and tumour. In the VM murine glioma model
we have shown at least a 30:1 concentration difference
between the concentration of aluminium phthalocyanine
extracted from normal mouse brain homogenate and the
concentration in homogenates of tumour bearing mouse
brain 24h after intravenous sensitisation (unpublished data).
In order therefore to establish whether or not selective
glioma necrosis beneath the surface of normal brain is
possible without damaging the overlying normal brain we
have first defined treatment parameters that do not damage
normal brain by measuring the end biological effect of PDT,
namely tissue necrosis. We have then used these parameters
to treat VM mice bearing intracranial tumours implanted
beneath the surface of the parietal lobe. We present here
some preliminary histological results.
The following method was employed. A synthetic photo-
sensitiser sulphonated aluminium chlorophthalocyanine
(ALSPc) was used for this study in contrast to previous
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studies that have used haematoporphyrin derivative.
ALSPc has the advantage that it is easily synthetised in
reproducible form (a solution containing an average of three
sulphonic acid groups per molecule). It is an effective
photosensitiser both in vitro and in vivo and it has a single
strong absorption peak in the visible spectrum at 675 nm
(Chan et al., 1986). Outbred mice, weighing between 20-30 g
were used for the normal studies and results compared with
studies on the VMDk murine glioma model. This is an
injectable model using a cell line (VMDk 497 P(1) passage
level 10-16) derived from a spontaneous murine astrocytoma
(Bradford et al., 1986). Cells were grown to confluence in
monolayer culture, harvested with trypsin and suspended in
Hank's balanced salt solution. Post weanling mice were
inoculated intracerebrally through the centre of the right
parietal bone (exposed by a midline skin incision) with 10j
aliquots of cell suspension containing 5 x 105'cells, using a
Hamilton syringe. A guarded 27 gauge needle was used so
that the inoculation depth was kept constant at 2mm.
Animals were exposed to light 7 days after inoculation when
tumours were still localised to the right parietal lobe.
Both normal and tumour bearing animals were sensitised
by i.v. injection into a tail vein with either five or
0.5mgkg-I of ALSPc. This was supplied in powder form by
Ciba-Geigy and dissolved in 0.9% saline so that between
0.05-0.1 ml of solution was injected into each animal.
Between 4 and 48 h after sensitisation the animals were
anaesthetised with a mixture of equal proportions of
diazepam (valium solution, 2mgml-1, diluted 1:5 with 0.9%
saline) and fentanyl/fluanisone solution (Hypnorm, diluted
1:10 in 0.9% saline). This mixture (0.1 ml) was given i.p. for
each 10g of body weight. The skin incision was reopened
and a right parietal craniectomy, 4mm in diameter was
fashioned using a model makers drill under high power
magnification, to expose the underlying cortex.
Red light (675nm) from an argon pumped dye laser
(Aurora; Cooper Medical) was then delivered as a 3mm
diameter, external beam (TEM mode 00) via a 200gm fibre
positioned perpendicular to the surface of the exposed brain.
The laser output at the end of the fibre was limited to 50mw
and the brain kept moist throughout the light exposure to
avoid hyperthermic damage to the cortex. The energy
delivered was controlled by varying the exposure time to
produce values from one to 200 Joules (14-2800Jcm-2).
Twenty-four to 48h after light exposure animals were
sacrificed by cervical dislocation, their brains fixed in 10%
formol saline, embedded in paraffin, cut in coronal section
and stained with haematoxylin and eosin. Maximum lesion
diameter was measured using a precalibrated microscope
graticule.
The relationship between mean lesion diameter and energy
in normal animals sensitised 48h prior to light exposure with
one of two doses of ALSPc and in unsensitised controls is
shown in Figure 1. At a dose of 5mgkg-1 all animals
exposed to 20 Joules died within 24h of light exposure. With
0.5mgkg-I ALSPc the lethal threshold was 200 Joules.
Equivalent sized lesions were produced by 10 Joules in
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Figure 1 Relationship between Mean Lesion Diameter and
Energy for two doses of ALSPc in non tumour bearing animals.
Five animals were used per treatment group but s.e. bars are
only shown if all 5 animals survived 24h. C=Control group of
unsensitised animals exposed to 200J of light.
animals sensitised with 5mgkg-1 and 100 Joules in animals
sensitised with 0.5mgkg-1. At this dose of ALSPc only 100
Joules produced lesions significantly larger (P<0.05) than
those produced by 200 Joules of light alone in unsensitised
animals. (Lesions in these animals could only have been
produced by hyperthermia and/or the surgery so they act as
controls.)
Tumour bearing animals were sensitised with 0.5mgkg-1
ALSPc and exposed to 50 Joules of 675nm light.
Representative sections of two such animals are shown in
Figures 2 and 3. The animal in Figure 2 had a tumour
positioned in the right hippocampal cortex which was also
growing along the needle track. The tumour had undergone
complete necrosis. Damage to the normal brain was limited
to an area around the tumour and the needle track. The
brain medial to the needle track and superficial to the
tumour received a greater light dose than the tumour yet
remained histologically intact. Figure 3 shows a section from
a brain containing a small tumour in the superficial hippo-
campal cortex. The tumour is necrotic but apart from very
superficial damage to the neocortex the normal brain is also
histologically intact.
This preliminary study was carried out to establish the
principle that selective glioma necrosis can be achieved with
PDT under conditions that mimic clinical practice, prior to
our main study which is to quantify in detail the effects of
ALSPc induced photodynamic necrosis on normal mouse
brain and on VM murine gliomas. A surgical study using an
injectable tumour model in a small mammal has three main
problems. First the model's size makes it technically difficult
to use. Second, being an injectable model there is the
possibility of non specific uptake of ALSPc around a
mechanical defect in the blood-brain barrier caused by the
needle. Animals inoculated intracerebrally with Hank's
solution alone do show some necrosis around the needle
track but the maximum diameter of lesions in these animals
is less than half that seen in tumour bearing animals. Finally
the depth to which tumour cells can be inoculated to
produce focal tumours in this model is limited to -2mm. It
is not possible, therefore, to define the maximum depth to
which selective necrosis could occur, which in theory should
be over 5mm for 675nm light (Svaasand & Ellingsen, 1983).
Nevertheless, this study does show that selective necrosis
of glioma cells in a tumour bed is possible with PDT, using
treatment parameters that do not damage normal brain
under conditions that mimic the geometry of a clinical
application. This has not been demonstrated with any of the
established methods of adjuvant glioma therapy and we
therefore believe that PDT is worthy of very thorough
evaluation. The study also shows that selectivity can only be
achieved if the effects of PDT on normal brain and tumour
are quantified precisely. Further experimental work is
Figure 2 Coronal section of the brain of a tumour bearing mouse sensitised with 0.5mgkg-I ALSPc 4h prior to exposure to 50J
of red light (675nm) and sacrificed 24h after light exposure (x 25 magnification). Arrows indicate the area of brain directly
exposed to the light. Insert shows a high power view of the tumour which has undergone complete necrosis (x 200 magnification).
nt= needle track, cc=corpus callosum, hc= hippocampal cortex, t=tumour.
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Figure 3 Corotnal section of the brain of a tumour bearing mouse sensitised with 0.5mgkg-' ALSPc, 24h prior to exposure to
5t)J of red light (675 nm) and sacrificed 24h after light exposure. Arrows indicate the area of brain directly exposed to the light.
Insert shows a high power view of the necrotic tumour. Magnifications and abbreviations are the same as for Figure 2.
required to optimise the selectivity between normal brain and
glioma tissue, to quantify light penetration in the brain and
to demonstrate increased survival in animal models before
the method can be considered ready for phase I clinical
trials.
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